Decentralized Clinical Trials Market Report 2026

The decentralized clinical trials market size has grown rapidly in recent years. It will grow from $8.77 billion in 2025 to $10.31 billion in 2026 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to increasing complexity of clinical trials, rising need for patient recruitment efficiency, expansion of digital health technologies, growing use of electronic data capture systems, increasing regulatory openness to decentralized models.

The decentralized clinical trials market size is expected to see rapid growth in the next few years. It will grow to $19.55 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to increasing adoption of hybrid trial designs, rising demand for faster drug development timelines, expansion of global virtual trials, growing use of ai-driven trial optimization, increasing focus on diverse patient participation. Major trends in the forecast period include increasing adoption of remote patient monitoring tools, growing use of virtual trial platforms, expansion of wearable-based data collection, rising implementation of real-time trial analytics, enhanced focus on patient-centric trial design.

The increasing emphasis on telemedicine is expected to drive growth in the decentralized clinical trials market in the coming years. Telemedicine delivers healthcare services remotely through digital communication technologies, allowing medical consultations and monitoring without requiring patients to visit healthcare facilities. This focus on telemedicine is largely driven by the need for accessible healthcare in response to global health challenges and social distancing measures. Decentralized clinical trials leverage telemedicine to remotely engage and monitor participants, reducing the need for in-person visits while enabling real-time data collection, broader access, and continuous oversight. For example, according to the Australian Bureau of Statistics (ABS), in 2023-24, 83.5% of males in Australia reported using telehealth services, up from 78.6% in 2022-23. This growing reliance on telemedicine is therefore fueling the expansion of the decentralized clinical trials market.

Leading companies in the decentralized clinical trials market are increasingly focusing on advanced solutions such as all-in-one, no-code clinical trials software to simplify trial setup and management, enhancing efficiency and patient engagement. Such software allows researchers to design, manage, and run trials without coding, while integrating patient recruitment, data capture, monitoring, and analytics into a single user-friendly platform. For instance, in August 2024, Medable, a U.S.-based clinical technology company, launched Medable Studio, an all-in-one, no-code software solution that streamlines the configuration, translation, validation, and deployment of electronic Clinical Outcome Assessments (eCOA), eConsent, Televisit, and sensors Plus in clinical trials. This platform enables biopharmaceutical companies to create protocol-fit study designs in hours instead of months, offering greater control, transparency, and speed, along with flexible self-service, full-service, or hybrid options, significantly reducing study startup timelines and costs. It aims to transform trial execution by making study builds faster, more efficient, and less dependent on external professional services.

In July 2023, Signant Health, a U.S.-based provider of evidence generation solutions for modern clinical trials, acquired DSG Inc. for an undisclosed amount. This acquisition enhances Signant Health’s eClinical solution suite by integrating DSG’s unified electronic data capture (EDC) and direct data capture (DDC) platform, providing more flexible and comprehensive support for both traditional and decentralized clinical trials. The acquisition strengthens operational efficiency, simplifies trial processes, and improves digital solutions for sponsors, sites, and contract research organizations (CROs). DSG Inc. specializes in providing unified EDC and DDC technology for site-based and decentralized clinical trials.

Major companies operating in the decentralized clinical trials market are Walgreens Boots Alliance Inc., Pfizer Inc., Oracle Corporation, Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Labcorp Holdings Inc., ICON Public Limited Company, Dassault Systèmes SE, LEO Pharma A/S, Verily Life Sciences LLC, ProPharma, Signant Health Holding Corp., PCM Trials, Huma Therapeutics Limited, Medable Inc., Science 37 Inc., Obvio Health, EmVenio Research Inc., Grove AI Inc., Phesi Inc.

North America was the largest region in the decentralized clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the decentralized clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the decentralized clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the decentralized clinical trials market by increasing costs of imported wearable devices, telemedicine hardware, remote monitoring sensors, and secure data platforms. Pharmaceutical companies and CROs in North America and Europe are most affected due to reliance on imported digital trial technologies, while Asia-Pacific faces cost pressure on device sourcing. These tariffs are increasing operational expenses for decentralized trials. However, they are also supporting local device manufacturing, regional digital health ecosystems, and innovation in cost-efficient virtual trial infrastructure.

The decentralized clinical trials market research report is one of a series of new reports that provides decentralized clinical trials market statistics, including decentralized clinical trials industry global market size, regional shares, competitors with a decentralized clinical trials market share, detailed decentralized clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the decentralized clinical trials industry. This decentralized clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Decentralized clinical trials are a contemporary approach to conducting clinical research that leverages digital tools and remote processes to engage participants beyond traditional trial sites. They facilitate real-time data collection and monitoring, improving trial efficiency. These trials also enhance accessibility, enabling broader and more diverse participation, while accelerating research timelines and reducing operational challenges.

The primary types of decentralized clinical trials are interventional, observational, and expanded access. Interventional decentralized trials involve assigning participants to receive specific interventions to assess their effects on health outcomes. Technologies employed include wearable devices, mobile health applications, telemedicine platforms, and electronic data capture systems, across study phases such as phase I, phase II, phase III, and phase IV. These trials are applied in therapeutic areas including oncology, cardiology, neurology, and infectious diseases, and are utilized by pharmaceutical companies, biotechnology firms, contract research organizations, regulatory authorities, and academic and research institutions.

The decentralized clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and retention, site management and monitoring, data management and analytics, regulatory compliance support, and telemedicine or virtual care solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The decentralized clinical trials market also includes sales of wearable health monitoring devices, electronic data capture systems, biosensors, remote patient monitoring equipment, and clinical trial management software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities, wholesalers, distributors, and retailers or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.